380 related articles for article (PubMed ID: 11590494)
1. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
[TBL] [Abstract][Full Text] [Related]
2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
4. Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients.
Kazanjian P; Tashima K; Hollander T; Kaul D
HIV Clin Trials; 2001; 2(3):213-8. PubMed ID: 11590530
[TBL] [Abstract][Full Text] [Related]
5. Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch.
Tomasoni LR; Patroni A; Torti C; Paraninfo G; Gargiulo F; Quiros-Roldan E; Uccelli MC; Airò P; Tinelli C; Carosi G; Castelli F;
HIV Clin Trials; 2003; 4(5):311-23. PubMed ID: 14583847
[TBL] [Abstract][Full Text] [Related]
6. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
7. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
8. Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.
Carosi G; Castelli F; Suter F; Maggiolo F; Orani AM; Pan A; Andreoni M; Vigevani GM; Maserati R; Mazzotta F; Tinelli C;
HIV Clin Trials; 2001; 2(5):399-407. PubMed ID: 11673814
[TBL] [Abstract][Full Text] [Related]
9. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
10. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
11. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
12. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
Lucas GM; Chaisson RE; Moore RD
AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
[TBL] [Abstract][Full Text] [Related]
13. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
[TBL] [Abstract][Full Text] [Related]
14. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F; Arribas JR; Miró JM; Costa MA; González J; Rubio R; Peña JM; Torralba M; Lonca M; Lorenzo A; Cepeda C; Vázquez JJ; Gatell JM;
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):343-50. PubMed ID: 15097150
[TBL] [Abstract][Full Text] [Related]
15. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
16. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.
Plana M; Martínez C; García F; Maleno MJ; Barceló JJ; García A; Lejeune M; Vidal C; Cruceta A; Miró JM; Pumarola T; Gallart T; Gatell JM
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):429-34. PubMed ID: 11981357
[TBL] [Abstract][Full Text] [Related]
17. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
[TBL] [Abstract][Full Text] [Related]
18. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
Easterbrook PJ; Newson R; Ives N; Pereira S; Moyle G; Gazzard BG
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):350-64. PubMed ID: 11468423
[TBL] [Abstract][Full Text] [Related]
19. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
20. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.
Clerici M; Seminari E; Suter F; Castelli F; Pan A; Biasin M; Colombo F; Trabattoni D; Maggiolo F; Carosi G; Maserati R
AIDS; 2000 Jan; 14(2):109-16. PubMed ID: 10708280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
